What Researchers Did
Researchers conducted an interim safety analysis of a randomized controlled trial (HOT-LoCO) to evaluate the safety of hyperbaric oxygen therapy (HBO) for long COVID.
What They Found
Twenty randomized subjects with long COVID exhibited significantly lower health-related quality of life (mean PF 31.75 vs 83.5 in norm data) and physical performance (mean 6MWT 442 meters vs 662 meters in norm data) compared to normative data. A total of 31 adverse events occurred in 60% of subjects, with 20 potentially related to HBO therapy, most commonly cough and chest pain or discomfort, though the Data Safety Monitoring Board deemed the therapy safe enough to continue.
What This Means for Canadian Patients
This interim safety report suggests that hyperbaric oxygen therapy for long COVID may be safe, potentially offering a future treatment option for Canadian patients experiencing persistent symptoms. However, further research is needed to confirm efficacy and establish clear guidelines before it can be widely adopted in clinical practice.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
This interim safety report is limited by its small sample size of 20 subjects and focuses solely on safety, not efficacy.